Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I-IIIA Completely Resected Non-small Cell Lung Cancers
Based on guidelines from the American Society of Clinical Oncology and Cancer Care Ontario.
These guideline summaries are shared for educational purposes only and are not intended to direct patient care. For detail on the specific recommendations and information about the evidence considered by the guideline developer, we encourage you to go to the original guideline statement cited below.
Adjuvant Systemic Therapy
Adjuvant chemotherapy is not recommended.
Adjuvant cisplatin-based chemotherapy is not recommended for routine use. A postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. Factors other than tumor stage to consider when making a recommendation for adjuvant chemotherapy are outlined after the adjuvant systemic therapy section of this guideline.
Adjuvant cisplatin-based chemotherapy is recommended.
Adjuvant Radiation Therapy
Adjuvant radiation therapy is not recommended.
Adjuvant radiation therapy is not recommended for routine use. A postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiotherapy for each patient with N2 disease.